BeiGene | A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

Beigene Study ID

BGB-11417-303

ClinicalTrials.gov ID

NCT06943872

EudraCT Number

2024-517131-52-00

Study Overview

Sex: All

Age: 18 Years / N/A

No Study Documents

Locations

Study Overview

Sex: All

Age: 18 Years / N/A

No Study Documents